IDEAYA Biosciences Future Growth
Future criteria checks 2/6
IDEAYA Biosciences is forecast to grow earnings and revenue by 13.3% and 64.2% per annum respectively. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be -28.8% in 3 years.
Key information
13.3%
Earnings growth rate
18.3%
EPS growth rate
| Biotechs earnings growth | 27.9% |
| Revenue growth rate | 64.2% |
| Future return on equity | -28.8% |
| Analyst coverage | Good |
| Last updated | 22 Oct 2024 |
Recent future growth updates
Recent updates
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Sep 20Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 64 | -234 | -246 | -231 | 12 |
| 12/31/2025 | 15 | -251 | -234 | -228 | 14 |
| 12/31/2024 | 8 | -203 | -158 | -163 | 14 |
| 6/30/2024 | 12 | -154 | -134 | -131 | N/A |
| 3/31/2024 | 16 | -129 | -135 | -131 | N/A |
| 12/31/2023 | 23 | -113 | -118 | -115 | N/A |
| 9/30/2023 | 23 | -103 | -116 | -115 | N/A |
| 6/30/2023 | 45 | -74 | -111 | -109 | N/A |
| 3/31/2023 | 47 | -68 | -98 | -95 | N/A |
| 12/31/2022 | 51 | -59 | -91 | -87 | N/A |
| 9/30/2022 | 50 | -53 | -85 | -80 | N/A |
| 6/30/2022 | 29 | -66 | -72 | -69 | N/A |
| 3/31/2022 | 32 | -55 | -64 | -62 | N/A |
| 12/31/2021 | 28 | -50 | -58 | -56 | N/A |
| 9/30/2021 | 36 | -37 | -53 | -51 | N/A |
| 6/30/2021 | 36 | -30 | 50 | 52 | N/A |
| 3/31/2021 | 27 | -31 | 50 | 51 | N/A |
| 12/31/2020 | 20 | -34 | 55 | 55 | N/A |
| 9/30/2020 | 9 | -40 | 58 | 58 | N/A |
| 6/30/2020 | N/A | -46 | -43 | -42 | N/A |
| 3/31/2020 | N/A | -44 | -40 | -39 | N/A |
| 12/31/2019 | N/A | -42 | -41 | -39 | N/A |
| 9/30/2019 | N/A | -40 | -40 | -38 | N/A |
| 6/30/2019 | N/A | -42 | -39 | -36 | N/A |
| 3/31/2019 | N/A | -38 | -34 | -32 | N/A |
| 12/31/2018 | N/A | -34 | -29 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDYA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDYA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDYA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDYA's revenue (64.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: IDYA's revenue (64.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDYA is forecast to be unprofitable in 3 years.